Sitemap
- Englisch
- maintrac
The maintrac® method detects, identifies and characterises circulating tumour cells in the blood. 15ml EDTA blood is required for this. Using antibodies, maintrac® detects the tumour cells quantitatively with the aid of a semi-automated fluorescence microscope.- Therapy monitoring
Continually determining the number of circulating epithelial tumour cells (CETCs) at regular intervals during cancer therapy makes it possible to monitor the treatment. - Anti-hormonal therapy
maintrac® is suitable for long-term monitoring during anti-hormonal therapy. Here, it is recommendable to determine the CETCs every three to six months. If the cell count is increasing, a change to the drug may be considered (e.g. a switch from tamoxifen to aromatase inhibitors or vice versa). - Drug testing
maintrac® makes it possible to determine the effectiveness of cytotoxic drugs (such as chemotherapeutic agents) before the treatment. For this, the CETCs from the patient's blood sample are mixed with the active agent to be tested. - Characteristics with therapeutic relevance
Certain active agents (so-called targeted therapies) are directed against characteristic features of the tumour. It is only if the tumour has these characteristics that the patient could benefit from the targeted therapy. maintrac® allows characterisation of the therapeutically-relevant features of the CETCs currently present in the blood.
- Therapy monitoring
- Research
One of the core competencies of simfo GmbH is research on the development of cancer and the development of metastases. Cancer cells (CETCs/CTCs) can reach other areas of the body via the bloodstream and develop metastases there. Based on the maintrac® method, procedures are being developed that are contributing to a better understanding of metastatic processes. - News
Find out about congresses, conferences and events at which simfo GmbH is represented. Get in touch with us and meet our staff. Any concerns you may have can be worked out in detail in a personal meeting. Naturally, we also offer our specialist seminars in Bayreuth. We look forward to meeting you.- Press
As one of the 15 most innovative European companies SIMFO GmbH was invited by the European Commission to the Bio International Convention (BIO) 2017 to present maintrac® liquid biopsy under the patronage of the EU. - Events
- Publications
- Press
- Company
- imprint
- privacy
- maintrac
- Englisch
- maintrac
The maintrac® method detects, identifies and characterises circulating tumour cells in the blood. 15ml EDTA blood is required for this. Using antibodies, maintrac® detects the tumour cells quantitatively with the aid of a semi-automated fluorescence microscope.- Therapy monitoring
Continually determining the number of circulating epithelial tumour cells (CETCs) at regular intervals during cancer therapy makes it possible to monitor the treatment. - Anti-hormonal therapy
maintrac® is suitable for long-term monitoring during anti-hormonal therapy. Here, it is recommendable to determine the CETCs every three to six months. If the cell count is increasing, a change to the drug may be considered (e.g. a switch from tamoxifen to aromatase inhibitors or vice versa). - Drug testing
maintrac® makes it possible to determine the effectiveness of cytotoxic drugs (such as chemotherapeutic agents) before the treatment. For this, the CETCs from the patient's blood sample are mixed with the active agent to be tested. - Characteristics with therapeutic relevance
Certain active agents (so-called targeted therapies) are directed against characteristic features of the tumour. It is only if the tumour has these characteristics that the patient could benefit from the targeted therapy. maintrac® allows characterisation of the therapeutically-relevant features of the CETCs currently present in the blood.
- Therapy monitoring
- Research
One of the core competencies of simfo GmbH is research on the development of cancer and the development of metastases. Cancer cells (CETCs/CTCs) can reach other areas of the body via the bloodstream and develop metastases there. Based on the maintrac® method, procedures are being developed that are contributing to a better understanding of metastatic processes. - News
Find out about congresses, conferences and events at which simfo GmbH is represented. Get in touch with us and meet our staff. Any concerns you may have can be worked out in detail in a personal meeting. Naturally, we also offer our specialist seminars in Bayreuth. We look forward to meeting you.- Press
As one of the 15 most innovative European companies SIMFO GmbH was invited by the European Commission to the Bio International Convention (BIO) 2017 to present maintrac® liquid biopsy under the patronage of the EU. - Events
- Publications
- Press
- Company
- imprint
- privacy
- maintrac
